You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Type of Drug for Psoriatic Arthritis

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000451678.43576.ba
Drug Watch
Abstract

* Apremilast (Otezla) is a phosphodiesterase-4 inhibitor that has been approved for use in the treatment of active psoriatic arthritis. Apremilast increases intracellular cyclic adenosine monophosphate, decreasing the levels of several proinflammatory mediators. The most common adverse effects are diarrhea, headache, and nausea. Apremilast may induce or exacerbate depression; serious depression is possible, although not common. Apremilast can also produce significant weight loss.

© 2014 Lippincott Williams & Wilkins. All rights reserved.